The drugmaker has reached a debt-for-equity exchange with healthcare investment firm Deerfield Management Co.
Under the agreement, the investment firm will acquire the company and wipe out $140 million in debt.
In the bankruptcy petition, Melinta listed about $500 million in assets and up to $500 million in liabilities, according to Bloomberg.
The drugmaker plans to operate normally through the bankruptcy process.
The company, founded in 2000, sells drugs that treat methicillin-resistant staphylococcus aureus, urinary tract and other bacterial infections.
More articles on pharmacy:
Drugmakers shift from clinical trials, mine EMRs for drug approvals
Roche buys international rights to Sarepta’s Duchenne drug for $750M
Former Aegerion sales rep defrauded insurers, stole identities to push cholesterol drug
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
